Squarepoint Ops LLC Increases Holdings in OrthoPediatrics Corp. $KIDS

Key Points

• Squarepoint Ops LLC nearly doubled its OrthoPediatrics position in the second quarter, acquiring 95,230 additional shares for a total stake valued at approximately $3.7 million. Institutional investors collectively own about 69% of the company.
• Analyst sentiment remains favorable, with nine Buy ratings, one Hold and one Sell; the consensus is Moderate Buy with a $26.44 average price target. Piper Sandler and BTIG Research recently raised their targets to $25 and $29, respectively.
• Insiders sold 2.1 million shares worth approximately $46.7 million over the past 90 days, including 302,369 shares each sold by Jennifer Pritzker and Director David Pelizzon. Separately, OrthoPediatrics exceeded quarterly revenue expectations with $70.51 million in revenue and an EPS loss of $0.26, better than analysts expected.

Squarepoint Ops LLC raised its holdings in shares of OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) by 95.0% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 195,468 shares of the company's stock after acquiring an additional 95,230 shares during the quarter. Squarepoint Ops LLC owned approximately 0.75% of OrthoPediatrics worth $3,739,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the business. Waverly Advisors LLC raised its position in shares of OrthoPediatrics by 6.7% during the 2nd quarter. Waverly Advisors LLC now owns 12,366 shares of the company's stock worth $237,000 after acquiring an additional 775 shares in the last quarter. California State Teachers Retirement System increased its stake in OrthoPediatrics by 397.1% in the second quarter. California State Teachers Retirement System now owns 4,553 shares of the company's stock valued at $87,000 after purchasing an additional 3,637 shares during the last quarter. Nantahala Capital Management LLC purchased a new position in OrthoPediatrics in the second quarter valued at approximately $4,636,002. Grandeur Peak Global Advisors LLC acquired a new stake in OrthoPediatrics during the second quarter worth approximately $954,000. Finally, Bank of America Corp DE acquired a new stake in OrthoPediatrics during the second quarter worth approximately $268,000. Hedge funds and other institutional investors own 69.05% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on KIDS shares. Piper Sandler restated an "overweight" rating and issued a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a report on Wednesday, August 5th. BTIG Research lifted their price target on shares of OrthoPediatrics from $24.00 to $29.00 and gave the stock a "buy" rating in a research note on Thursday, August 20th. TD Cowen reiterated a "buy" rating on shares of OrthoPediatrics in a research note on Monday, June 15th. Truist Financial set a $22.00 price target on shares of OrthoPediatrics in a research report on Wednesday, August 5th. Finally, Weiss Ratings upgraded shares of OrthoPediatrics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Wednesday, August 5th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $26.44.

Insider Activity at OrthoPediatrics

In related news, major shareholder Jennifer Pritzker sold 302,369 shares of the stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the completion of the sale, the insider owned 6,201,764 shares in the company, valued at $130,299,061.64. This represents a 4.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David Pelizzon sold 302,369 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the sale, the director owned 6,201,764 shares of the company's stock, valued at approximately $130,299,061.64. This represents a 4.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 2,100,000 shares of company stock worth $46,747,931 in the last 90 days. 32.50% of the stock is owned by insiders.

Key OrthoPediatrics News

Here are the key news stories impacting OrthoPediatrics this week:

• Positive Sentiment: OrthoPediatrics crossed the $70 million revenue level and reportedly increased its guidance, signaling continued demand for its pediatric orthopedic products and potentially stronger future growth. OrthoPediatrics Crosses $70M as Guidance Climbs Higher
• Positive Sentiment: Analyst sentiment remains favorable: nine analysts rate the stock Buy, one rates it Hold and one rates it Sell. The consensus rating is Moderate Buy with an average price target of $26.44; BTIG and Needham recently raised their targets to $29 and $35, respectively.
• Positive Sentiment: Institutional ownership is substantial at approximately 69%, while several investment firms—including Millennium Management, BlackRock, Granahan Investment Management and Wasatch Advisors—have recently increased or initiated positions.
• Neutral Sentiment: Reported short interest was zero shares as of September 10, leaving no meaningful short-covering catalyst or bearish short-position overhang.
• Negative Sentiment: Director David Pelizzon, also identified in related filings as major shareholder entities associated with Jennifer Pritzker and Squadron Capital, sold 302,369 shares at an average price of $21.01 for approximately $6.35 million. The sale reduced the reported holding by 4.65%, which may pressure sentiment, although the insider still retained about 6.2 million shares. SEC Insider Sale Filing

OrthoPediatrics Trading Up 2.3%

KIDS opened at $22.06 on Friday. The firm has a market cap of $575.99 million, a price-to-earnings ratio of -13.13 and a beta of 0.99. OrthoPediatrics Corp. has a 52 week low of $14.42 and a 52 week high of $26.74. The business's 50 day moving average is $22.01 and its two-hundred day moving average is $19.04. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. The business had revenue of $70.51 million during the quarter, compared to the consensus estimate of $68.21 million. OrthoPediatrics had a negative return on equity of 8.10% and a negative net margin of 15.72%. On average, research analysts predict that OrthoPediatrics Corp. will post -1.14 EPS for the current year.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company's product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.

Want to see what other hedge funds are holding KIDS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.